Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 14/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.69 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.69 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.66 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.66 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.66 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Codeinone SCHEMBL101725 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2PDE4D | |
| Codeinone SCHEMBL13952981 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2PDE4D | |
| Codeinone SCHEMBL13633530 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2PDE4D | |
| Codeinone SCHEMBL13154678 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2PDE4D | |
| Codeinone SCHEMBL12137788 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2PDE4D | |
| Codeinone SCHEMBL14192923 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2PDE4D | |
| Codeinone SCHEMBL3107493 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2PDE4D | |
| Codeinone SCHEMBL29375985 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2PDE4D | |
| Codeinone SCHEMBL7707098 | 0.99 | OPRM1 (0.98) | OPRM1OPRK1OPRD1MRGPRX2PDE4D | |
| Codeinone SCHEMBL11533410 | 0.95 | OPRM1 (0.91) | OPRM1OPRK1OPRD1MRGPRX2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125725-A1 | Compositions And Methods For Making Benzylisoquinoline Alkaloids, Morphinan Alkaloids, Thebaine, And Derivatives Thereof | ANTHEIA INC (US) | 2026-05-07 | — | — | US | claimed |
| US-20260103736-A1 | Methods Of Improving Production Of Morphinan Alkaloids And Derivatives | ANTHEIA INC (US) | 2026-04-16 | — | — | US | claimed |
| US-20250283129-A1 | PROCESS | SUN PHARMACEUTICAL INDUSTRIES AUSTRALIA PTY LIMITED (AU) | 2025-09-11 | — | — | US | claimed |
| EP-4594342-A2 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | Antheia, Inc. (US) | 2025-08-06 | — | — | EP | claimed |
| US-20250179543-A1 | NORCOCLAURINE SYNTHASES WITH INCREASED ACITVITY | RIVER STONE BIOTECH INC (US) | 2025-06-05 | — | — | US | claimed |
| US-20250144067-A1 | PERSONALIZED STARVATION THERAPY FOR CANCER | FAETH THERAPEUTICS, INC. | 2025-05-08 | — | — | US | claimed |
| US-12060361-B2 | Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone | PURDUE PHARMA L.P. (US) | 2024-08-13 | — | — | US | claimed |
| US-20240240194-A1 | TRANSCRIPTION FACTOR | SUN PHARMACEUTICAL INDUSTRIES AUSTRALIA PTY LIMITED (AU) | 2024-07-18 | — | — | US | claimed |
| US-20240218408-A1 | Methods of Producing Epimerases and Benzylisoquinoline Alkaloids | HERCULES CAPITAL, INC., AS AGENT | 2024-07-04 | — | — | US | claimed |
| US-20240209403-A1 | METHODS OF PRODUCING MORPHINAN ALKALOIDS AND DERIVATIVES | HERCULES CAPITAL, INC., AS AGENT | 2024-06-27 | — | — | US | claimed |
| US-5571685-A | POLYPEPTIDES IN SYNTHESIS OF ANALGESICS | MACFARLAN SMITH LIMITED (GB) | 1996-11-05 | — | — | US | claimed |
| EP-0527975-B1 | Codeinone derivatives and their pharmaceutical use | ALKALOIDA VEGYESZETI GYAR (HU) | 1996-10-02 | — | — | EP | claimed |
| EP-0649465-A1 | MORPHINONE REDUCTASE FOR THE PREPARATION OF HYDROMORPHONE AND HYDROCODONE | MACFARLAN SMITH LIMITED (GB) | 1995-04-26 | — | — | EP | claimed |
| WO-1994000565-A1 | MORPHINONE REDUCTASE FOR THE PREPARATION OF HYDROMORPHONE AND HYDROCODONE | MACFARLAN SMITH LIMITED (GB) | 1994-01-06 | — | — | WO | claimed |
| EP-0527975-A1 | PHARMACEUTICAL COMPOSITION AND USE. | ALKALOIDA VEGYESZETI GYAR (HU) | 1993-02-24 | — | — | EP | claimed |
| WO-1992013534-A1 | PHARMACEUTICAL COMPOSITION AND USE | ALKALOIDA CHEMICAL COMPANY LTD. (HU) | 1992-08-20 | — | — | WO | claimed |
| US-4277604-A | Facile synthesis of codeine precursors from thebaine | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1981-07-07 | — | — | US | claimed |
| US-4140687-A | Process for the preparation of 8-halodihydrocodeinone hydrohalides and codeine | MACFARIAN SMITH LIMITED (GB) | 1979-02-20 | — | — | US | claimed |
| US-4054566-A | Process for converting neopinone to codeinone | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1977-10-18 | — | — | US | claimed |
| US-4052402-A | PROCESS FOR SYNTHESIZING CODEINONE FROM THEBAINE | FABRICA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS ABELLO, S.A. (ES) | 1977-10-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103736-A1 | Methods Of Improving Production Of Morphinan Alkaloids And Derivatives | OPRK1, OPRM1, OPRD1 | OPRM1 2/4885OPRK1 1/4885OPRD1 3/4885 |
| US-20260125725-A1 | Compositions And Methods For Making Benzylisoquinoline Alkaloids, Morphinan Alkaloids, Thebaine, And Derivatives Thereof | OPRD1, OPRM1, OPRK1 | OPRM1 2/4885OPRK1 3/4885OPRD1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.